Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

OUCRU researchers are proud to be involved in HECTOR – an interdisciplinary, multi-national research consortium which is investigating the genetic factors that contribute to antibiotic resistance.

Researcher feeding birds

Dr Ngo Thi Hoa, the leader of this collaboration in Vietnam and Oxford says: “The use of antibiotics in agriculture contributes substantially to the development of antibiotic resistant bacteria; particularly in E. coli ­- a type of bacteria that exists normally in humans and animals, but can sometimes cause opportunistic infections. However, we don’t fully understand how frequently bacteria and/or antibiotic resistance genes are transmitted between animals and humans. Results of this collaborative project will shed light on whether genetic factors of E. coli could be associated with their colonisation and spread between animals and humans. It will also tell us about how commonly the bacteria we study are carrying antibiotic resistance genes.”

Antibiotics have revolutionized medicine and saved countless lives. Their discovery represented a quantum leap in the treatment of infectious diseases. Sadly, many bacteria are now resistant to multiple antibiotics, to the extent that resistant strains have become a major public health threat. There is a rising fear that bacterial infections might even become untreatable in the future. Many different factors have contributed to this situation including horizontal resistance gene transfer within and between bacteria species.

An example of how antibiotic resistant bacteria can spread between animals and humans can be found in the case of the antibiotic drug colisitin. Discovered roughly 70 years ago, doctors stopped using colistin in human medicine because it can be highly toxic, but it is still used in veterinary medicine, mostly for treating intestinal infections. Nowadays, in the wake of increasing numbers of severe human infections caused by multidrug-resistant Gram-negative bacteria, colistin has become a key last resort drug. Recently, a plasmid-encoded colistin resistance gene was isolated from an animal-associated E. coli strain, and subsequently found worldwide on multi-resistance plasmids from bacteria isolated from humans, animals, retail meat and environmental samples. This indicated that even colistin, a last-resort antibiotic, is now under threat.

The HECTOR consortium will be looking specifically at many E. coli isolates from human, animal and environmental sources in Europe and Vietnam. They will look at genetic factors in the isolates that might contribute to the ability of the E. coli to live in a specific host or environment. The consortium will also look at how antibiotic resistant genes are spread in E. coli. Then, they will use that data to set up a mathematical model that can predict the preferred host for the bacteria (e.g., pigs, chickens, humans etc.) and predict how these antibiotic resistance genes might be transmitted. This model will enable scientists to develop risk assessments on transmission of bacteria between animals and humans and to design and set up targeted interventions to prevent and reduce such transmission in the future.

The HECTOR consortium brings together seven academic and public health research groups from Germany, The Netherlands, Spain, the United Kingdom and Vietnam from the fields of human and veterinary medicine, basic science and bioinformatics. HECTOR stands for Host restriction of Escherichia Coli on Transmission dynamics and spread Of antimicrobial Resistance. The HECTOR consortium has received funding for three years from the Joint Programming Initiative on Antimicrobial resistance (JPIAMR) from the EU framework program Horizon2020 through the MRC to undertake this work.

Similar stories

OUCRU scientists identify combination of biological markers associated with severe dengue

Nguyen Lam Vuong, Sophie Yacoub & colleagues have identified a combination of biological markers in patients with dengue that could predict whether they go on to develop moderate to severe disease. Biomarkers are used to identify the state or risk of a disease in patients; these findings could aid the development of biomarker panels for clinical use and help improve triage and risk prediction in patients with dengue.

What does the Oxford Malaria vaccine mean for Asia?

A trial in infants and toddlers in Burkina Faso showed that experimental malaria vaccine R21/MM confers 77% protection, an unprecedented level and the first malaria vaccine to exceed WHO’s goal of 75% efficacy. While a larger trial is needed to assess its safety and efficacy, R21/MM may substantially reduce child mortality in Sub-Saharan Africa. But this vaccine may be less relevant to Asia Pacific where malaria causes severe morbidity and mortality in all age groups, asymptomatic malaria infections are frequent, and the vaccine may not be effective against P. vivax.

RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

Professors Peter Horby and Guy Thwaites recognised in Queen’s Birthday Honours

The pioneering work of members of the University of Oxford has been recognised in The Queen's Birthday Honours List. The honorands include Professor Peter Horby and six researchers that have played key roles in leading the University’s response to the Coronavirus pandemic, from the development of new vaccines to the discovery of new drug treatments. Professor Guy Thwaites is appointed a Member of the Order of the British Empire.

RECOVERY trial finds aspirin does not improve survival for patients hospitalised with COVID-19

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for patients hospitalised with COVID-19. Patients with COVID-19 are at increased risk of blood clots forming in their blood vessels, particularly in the lungs. Between November 2020 and March 2021, the RECOVERY trial included nearly 15,000 patients hospitalised with COVID-19 in an assessment of the effects of aspirin, which is widely used to reduce blood clotting in other diseases. There was no significant difference in the primary endpoint of 28-day mortality

The COVID-19 International Modelling Consortium (CoMo Consortium) enters a new phase

Created in March 2020 to assist policymakers to make use of existing evidence in mathematical and epidemiological models to inform strategies for minimising the impact of COVID-19, the CoMo Consortium brings together mathematical modellers, epidemiologists, health economists and public health experts from more than 40 countries across Africa, Asia and South and North America.